Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

257.12
+2.120.83%
Post-market: 257.600.4800+0.19%19:57 EDT
Volume:4.31M
Turnover:1.11B
Market Cap:454.43B
PE:72.64
High:259.61
Open:253.92
Low:253.92
Close:255.00
52wk High:267.47
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:1.00
T/O Rate:0.24%
Dividend:6.83
Dividend Rate:2.66%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-76.57
PE(LYR):108.95

Loading ...

Uni-Bio Science H1 Revenue Falls 12% on Pricing Changes

Reuters
·
Aug 26

China's Shandong Xinhua Profit Drops on Domestic, International Competition

Reuters
·
Aug 25

China's Innovent Biologics H1 Revenue, Profit Rise on Strong Product Sales

Reuters
·
Aug 25

Austar Lifesciences H1 Profit Drops on Higher R&D Spending

Reuters
·
Aug 25

WuXi Biologics H1 Net Profit up on Margin Expansion

Reuters
·
Aug 25

Stick with Value Stocks Until Everyone Starts Talking About Them - and as of Now They're Still Under the Radar, This Wall Street Firm Says

Dow Jones
·
Aug 25

Molecular Partners H1 Net Loss Narrows on Lower R&D Expenses

Reuters
·
Aug 25

Oruka Therapeutics Names Todd Edwards Chief Commercial Officer

Reuters
·
Aug 25

Is AbbVie (ABBV) Fairly Valued As New Lung Cancer Data Impresses?

Simply Wall St.
·
Aug 25

ANI Pharma Appoints Henry Gosebruch to Board of Directors

Reuters
·
Aug 24

Johnson & Johnson, AbbVie, Chevron, Energy Transfer, Home Depot Shaken

TIPRANKS
·
Aug 22

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 22

AbbVie Expands Aesthetics Pipeline With New Phase 2 Forehead Lines Study

TIPRANKS
·
Aug 22

AbbVie Targets Pediatric Alopecia With New Phase 3 Trial: What Investors Should Watch

TIPRANKS
·
Aug 22

AbbVie’s Emraclidine Schizophrenia Study Ends Early: What Investors Need to Know Now

TIPRANKS
·
Aug 22

AbbVie Targets Next-Gen BOTOX Combo With New Glabellar Lines Study

TIPRANKS
·
Aug 21

AbbVie Price Target Raised to $303.00/Share from $298.00 by Piper Sandler

Dow Jones
·
Aug 21

AbbVie price target raised to $303 from $298 at Piper Sandler

TIPRANKS
·
Aug 20

Piper Sandler Adjusts Price Target on AbbVie to $303 From $298, Maintains Overweight Rating

MT Newswires Live
·
Aug 20

U.S. Research Roundup-Amgen, Analog Devices, Moderna

Reuters
·
Aug 20